0000000000896650

AUTHOR

A Peydró

showing 2 related works from this author

Hydrodynamic liver gene transfer mechanism involves transient sinusoidal blood stasis and massive hepatocyte endocytic vesicles

2005

The present study contributes to clarify the mechanism underlying the high efficacy of hepatocyte gene transfer mediated by hydrodynamic injection. Gene transfer experiments were performed employing the hAAT gene, and the efficacy and differential identification in mouse plasma of human transgene versus mouse gene was assessed by ELISA and proteomic procedures, respectively. By applying different experimental strategies such as cumulative dose-response efficacy, hemodynamic changes reflected by venous pressures, intravital microscopy, and morphological changes established by transmission electron microscopy, we found that: (a) cumulative multiple doses of transgene by hydrodynamic injection…

TransgeneGenetic VectorsMolecular Sequence DataEnzyme-Linked Immunosorbent AssayVena Cava InferiorBlood stasisGene deliveryBiologyMiceGeneticsmedicineAnimalsHumansMolecular BiologyPortal VeinCytoplasmic VesiclesGenetic transferGene Transfer TechniquesBlood flowMolecular biologyEndocytosisCell biologyMice Inbred C57BLMicroscopy ElectronEndocytic vesiclemedicine.anatomical_structurealpha 1-AntitrypsinHepatocyteHepatocytesMolecular MedicineVenous PressureIntravital microscopyLiver CirculationGene Therapy
researchProduct

Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis

2016

OBJECTIVE: To describe the clinical characteristics and evolution of our series of medication-related osteonecrosis of the jaws (MRONJ) associated with denosumab in osteoporotic patients. MATERIAL AND METHODS: We present 10 new cases of MRONJ in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous bisphosphonate intake, and the clinical characteristics associated with the osteonecrosis, such as local contributing factors, symptoms, and evolution after treatment. RESULTS: The mean number of denosumab doses was 3.4 2.2. In 90% of patients, there was a prior history of oral bisphosphonate intake, with a mean duration of 46.78 25.11 months. The most c…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisDentistryOdontología03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansStage (cooking)General DentistryAgedSclerosisMedicamentoBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industry030206 dentistryMiddle AgedBisphosphonatemedicine.diseaseBone Density Conservation AgentsDenosumabOtorhinolaryngologyDental extraction030220 oncology & carcinogenesisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabTomography X-Ray ComputedOsteonecrosis of the jawbusinessmedicine.drugOral Diseases
researchProduct